13 patents
Utility
Motile sperm domain containing protein 2 antibodies and methods of use thereof
11 Jul 23
The present disclosure relates to antibodies or antigen binding fragments thereof that specifically bind to Motile Sperm Domain Containing Protein 2 (MOSPD2) and methods of using the same.
Itzhak Mendel, Niva Yacov, Erez Feige, Eyal Breitbart
Filed: 9 Sep 21
Utility
Treatment Methods Using Adenovirus
20 Oct 22
The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor or inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter.
Eyal BREITBART, Andrea LEUBITZ, Erez FEIGE, Richard PENSON
Filed: 22 Mar 22
Utility
Methods of Anti-tumor Therapy
16 Jun 22
The disclosure provides methods of treating a tumor in a subject in need thereof comprising administering to the subject the combination of an effective dose of a vector comprising a Fas-chimera gene operably linked to an endothelial cell-specific promoter and an effective dose of an immune checkpoint inhibitor.
Tamar RACHMILEWITZ MINEI, Itzhak MENDEL, Niva YACOV, Eyal BREITBART
Filed: 13 Apr 20
Utility
Motile Sperm Domain Containing Protein 2 Antibodies and Methods of Use Thereof
28 Apr 22
The present disclosure relates to antibodies or antigen binding fragments thereof that specifically bind to Motile Sperm Domain Containing Protein 2 (MOSPD2) and methods of using the same.
Itzhak MENDEL, Niva YACOV, Erez FEIGE, Eyal BREITBART
Filed: 9 Sep 21
Utility
Treatment methods using adenovirus
26 Apr 22
The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor by inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter.
Eyal Breitbart, Andrea Leubitz, Erez Feige, Richard Penson
Filed: 23 Jul 18
Utility
Methods of inducing responsiveness to anti-angiogenic agent
7 Dec 21
The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
Andrea Rachel Leubitz, Naamit Sher, Erez Feige, Eyal Breitbart
Filed: 8 Jul 19
Utility
Diagnostic Methods for Anti-angiogenic Agent Therapy
21 Oct 21
The disclosure provides methods of treating a tumor in a subject who is capable of exhibiting a change in at least one plasma biomarker or cell surface biomarker after administration of at least one priming dose of a vector which comprises a Fas-chimera gene operably linked to an endothelial cell-specific promoter.
Itzhak MENDEL, Eyal BREITBART
Filed: 22 Oct 18
Utility
Motile Sperm Domain Containing Protein 2 and Cancer
1 Apr 21
Disclosed herein are methods of treating, reducing the incidence of, or preventing one or more activities in or of a cancer cell, methods of treating, reducing the incidence of, or preventing migration or metastasis of a cancer cell, methods of treating, reducing the incidence of, or preventing a cancer by reducing tumor associated macrophages (TAMs) or their migration, and methods of treating, reducing the incidence of, or preventing a cancer (including metastatic cancer), for example, with an inhibitor of Motile Sperm Domain containing Protein 2 (MOSPD2).
ITZHAK MENDEL, Oshrat PROPHETA-MEIRAN, Yaniv SALEM, Anat SHOHAM, Niva YACOV, Eyal BREITBART
Filed: 13 Oct 20
Utility
Motile Sperm Domain Containing Protein 2 and Inflammation
18 Mar 21
Disclosed herein are methods of treating, preventing, or reducing the incidence of an inflammatory disease or disorder and methods of inhibiting, preventing, or reducing the incidence of one or more activities in a cell with an inhibitor of a Motile Sperm Domain containing Protein 2 (MOSPD2).
ITZHAK MENDEL, Oshrat Propheta-Meiran, Yaniv Salem, Anat Shoham, Eyal Breitbart
Filed: 14 Sep 20
Utility
Methods and Compositions for Tumor Radiosensitization
11 Mar 21
Disclosed herein are methods and compositions for radiosensitizing tumor in subjects receiving radiation therapy by administering a gene therapy construct that results in expression of a secretory radiosensitizing agent in tumor endothelium.
Richard N. KOLESNICK, Branka STANCEVIC, Michel SADELAIN, Zvi FUKS, Nira VARDA-BLOOM, Dror HARATS
Filed: 27 Aug 20
Utility
Bispecific Antibodies to MOSPD2 and T Cell- or NK Cell-specific Molecules
30 Dec 20
Disclosed herein are bispecific antibodies or antigen binding fragments thereof that specifically bind to Motile Sperm Domain Containing Protein 2 (MOSPD2) and to a T cell-specific or NK cell-specific receptor molecule, pharmaceutical compositions and kits containing the same, and methods of making and using the same.
Itzhak MENDEL, Yaniv SALEM, Eyal BREITBART
Filed: 12 Mar 19
Utility
Methods of Inducing Responsiveness to Anti-angiogenic Agent
12 Feb 20
The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
Andrea Rachel LEUBITZ, Naamit SHER, Erez FEIGE, Eyal BREITBART
Filed: 7 Jul 19
Utility
Oxidized lipids and methods of use thereof
4 Nov 19
The present invention is directed to oxidized lipids and pharmaceutical compositions comprising the same.
Eti Kovalevski Ishai, Itzhak Mendel, Yaniv Salem, Niva Yacov, Eyal Breitbart
Filed: 15 Aug 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first